Celltrion ranked the first in the local brand reputation of listed pharmaceutical companies in June, followed by Samsung BioLogics and Celltrion Healthcare.
The Korea Corporate Reputation Research Institute (KCRRI) analyzed over 115 million pieces of 120 listed drugmakers from May 24 to June 24 and released the result on Thursday.
The institute gets brand reputation index (BRI) through dividing consumer activity-related big data on a brand by participation index (PI), communication index (CMI), community index (CI), and market index (MI).
Celltrion took the first place with a PI of 2,991,124, CMI of 2,227,410, CI of 894,853, and MI of 8,765,151, scoring 14,878,538 in total BRI, which was a 55.77 percent jump from last month.
Samsung BioLogics came in second with BRI of 1,464,601 by scoring 2,003,994 in PI, 1,166,348 in CMI, 368,937 in CI, and 10,925,322 in MI. The company’s BRI in June was up 34.5 percent from May.
“Celltrion brand aims to develop and produce various therapeutic proteins such as anticancer drugs based on biotechnology and animal cell mass culture technology,” said Gu Chang-hwan, director of the institute.
As the company has Asia’s largest production facilities that can make 140,000 liters of animal cell culture protein-based pharmaceutical products, it has a high corporate brand value, he went on to say.
“The company plans to build a third plant by taking into account development schedules and demands. It also obtained FDA approval for Remsima, the world’s first autoimmune disease treatment, in 2016,” he added.
<© Korea Biomedical Review, All rights reserved.>